Market Research Blog – Page 11624 – New Product Development

Sustained Release Excipients Market Scope of Current and Future Industry 2026

The sustained release excipients market is largely dominated by local manufactures who are competing on the basis of pricing in the market.

The fragmented nature of the market decreases the profitability of the business.

However, growing awareness about sustained release excipients and lack of test specificity and sensitivity for sustained release excipients manufactured by local companies have increased the revenue opportunities for the global manufacturers in pharmaceutical excipients.

Companies, such as BASF Corporation, Ashland Global Holdings Inc. and The Dow Chemical Company hold more than 42.8% revenue share in the global sustained release excipients market.

The companies operating in the sustained release excipients market are collaborating with local distributors to increase the penetration of their products in the sustained release excipients market.

Request a sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-7580

Abusive Consumption of Drugs (Pain Killers) Increasing the Incidence of Chronic Diseases Across North America.

Sustained release formulations are gaining popularity as they help in maintaining patient-safety through reduced number of medicine dosages, but having increased drug efficacy.

From a market point of view, reduced doses improve treatment compliance, which could help higher unit sales and so their revenues.Furthermore, from the patient point of view, better therapeutic outcomes are expected due to improved drug tolerance and efficacy leading to lower switching costs and greater physician loyalty.

Increment of Diseases Across the Globe

The prevalence of chronic as well as acute diseases is increasing across the globe. For the treatment of these diseases, doctors prescribe medicines.

Medicines usually contain excipients along with the active pharmaceutical ingredients. A huge demand for medicines is witnessed because of increasing prevalence of chronic diseases.

They are high in demand in Asia Pacific because of huge volume in this region.Sustained release excipients release the drug slowly so that it reaches the target site.

An excipient can be used in many ways. Due to this fact it is in great demand. Sustained release excipients reduce the indirect cost associated with conventional excipients.

Vertical Integration of Sustained Release Excipients Service Providers

Sustained release excipients service providers are offering their services through retail channels.

Increasing innovative collaborative research opportunities in pediatric formulations is being pushed through evolution of new regulations, additional funding opportunities, and increased public-private partnerships.

Request a TOC@ https://www.futuremarketinsights.com/toc/rep-gb-7580

This has been focused to development of excipients used in all kinds of excipients such as oral solid dosage formulations and liquid pediatric formulation, which are flexible, dispersible and multi-functional.

Furthermore, continued prioritization of unmet medical needs in pediatrics is expected to drive demand for these excipients and oral formulations in the forthcoming years.

Growing Impact of Drug Abuse on Public Health

Substance abuse has high impact on the health of individuals and their families.

Prolonged drug and alcohol abuse may lead to mental illness and chronic diseases, such as diabetes and heart diseases, cancer, which in turn, can create high economic burden on the society.

In order to curb this economic burden caused by drug abuse, governments are focusing on prevention and early intervention strategies are expected to drive demand for drugs of abuse.

For instance, according to the Centers for Disease Control and Prevention (CDC), nearly 10 million individuals aged 55 and above were reported to seek treatment for cancer across the globe. in 2014.

Moreover, it is estimated that nearly US$ 600 Bn is spent on addressing the impact caused by substance abuse each year in the U.S.

Competitive Landscape

Competition section of the sustained release excipients market features profiles of key players operating in the industry based on their market shares, differential strategies, product offerings, marketing approach and company dashboard.

Examples of some of the key players featured in this report include FMC Corporation, Ashland Global Holdings, BASF Corporation,

The Dow Chemical Company, Roquette Freres S.A. Colorcon Inc., Croda International Inc.The key manufacturers of sustained release excipients are focusing on novel marketing strategies to increase product penetration.

The companies offering point-of-care sustained release excipients are concentrating on price floor strategies.

Ask An expert here @ https://www.futuremarketinsights.com/askus/rep-gb-7580

These companies are offering their products with lucrative discounts.

Conventional distribution channels, such as retail pharmacies, drug stores, supermarkets and hypermarkets are expected to be the key targets channel for local manufacturers.

Definition:

The sustained release excipients are one of the type of excipients that are added to the drug along with active pharmaceutical ingredients of medication.

Sustained release excipients are pharmacologically non-active ingredients of the drug formulation.

About the Report:

The report offers a comprehensive evaluation of the business opportunities prevailing in the sustained release excipients market along with insights on the sustained release excipients consumption trend, disease incidences, and awareness level for sustained release excipients and sustained release excipients market competition.

The report elaborates on the macroeconomic factors influencing the dynamics of sustained release excipients market and its futuristic potential.

Research Methodology

The sustained release excipients market has been estimated based on supply-demand approach. The market was first calculated based on allergy test volume conducted in different region/countries.

The test volume was estimated based on the incidence rate of various types of allergies in the top 20 countries globally.

Other qualitative factors analyzed during test volume estimation include awareness level for point care sustained release excipients, the recurrence rate of allergy reaction and others.

This information is further validated with rigorous primary research (including interviews, surveys, in-person interactions, and viewpoints of seasoned analysts) and secondary research (including verified paid sources, authentic trade journals, and resourceful databases).

The research study on sustained release excipients market also includes top trends and macro as well as microeconomic factors shaping the sustained release excipients market.

With this approach, the report on sustained release excipients market anticipates the industry attractiveness of every major segment in sustained release excipients market over the forecast period.

Segmentation

The report offers a comprehensive taxonomy of sustained release excipients market based on product type, end user, route of administration route, and region.The sustained release excipients are sold for various types of test samples, such as blood, skin, etc.These sustained release excipients are used by pharmaceutical companies, biopharmaceutical companies, neutraceutical companies, and for various type of sustained release excipients, such as food allergies, drug allergies, latex allergies and other types of allergies.End-use segments in the sustained release excipients market which are a part of this sustained release excipients market report include pharmaceutical companies, biopharmaceutical companies and other end users, such as nutraceutical manufacturers and contract manufacturing organisations.

The sustained release excipients market has been analyzed across regions of North America, Latin America, Europe, CIS & Russia, Asia Pacific and MEA.

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Unit No: 1602-006
Jumeirah Bay 2
Plot No: JLT-PH2-X2A
Jumeirah Lakes Towers
Dubai
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Plant Derived Proteins Market Insights, Deep Analysis of Key Vendor in the Industry by 2029

Production and commercialization of biopharmaceutical proteins with higher therapeutic efficacy have formed a progressive landscape that continues to push the growth of plant derived proteins market. A new Future Market Insights (FMI) report forecasts that the plant derived proteins market will experience a major upturn towards 2029, reaching a value of around US$ 185 Mn. Production of three main therapeutic protein classes, including antibodies, vaccines, and replacement proteins such as albumin, insulin, growth factors, and cytokines will remain industry’s prime focus area.

Plant derived proteins are recognized as natural and environmentally-sustainable than microbial and mammalian cells. Owing to these benefits, there has been an increasing demand for such proteins from biopharmaceutical companies, as raw materials for therapeutic drug production, creating an absolute opportunity for growth of the plant derived proteins market.

Key Takeaways of Plant Derived Proteins Market Study

The production of therapeutic proteins for disease treatment will gain traction, contributing more than 70% to global market revenues in 2029.
Owing to low setup cost, transient plant expression systems (carrot or tobacco) remains preferred among protein manufacturers.
Regenerative medicine-therapeutic agents continue to be the leading application area, on the back of their relatively cheap price point.
Biopharmaceutical companies represent the leading consumer industry of plant derived proteins, with over 50% share in market throughout the forecast period.
North America continues to lead, whereas East Asia holds the promise of lucrative opportunities, owing to several healthcare programs.

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-11038

Acquisition Key Strategy Followed by Leading Market Players

Leading manufacturers in the plant derived proteins market are focusing on regional acquisition strategy to enhance their product portfolio and expand their regional presence. For instance, in 2017, Denka buys pharming pioneer Icon Genetics, which is a leading manufacturers of therapeutic proteins in plants. In 2014, Kentucky BioProcessing, Inc. was acquired by Reynolds American Inc., which is a wholly owned subsidiary of tobacco manufacturing company British American Tobacco plc.

Interested in more insights on the build-up of plant derived proteins market?

Plant derived proteins market, a new study from future market insights, opines on the production of plant derived proteins from 2014 – 2018 and presents demand projections from 2019 – 2029 on the basis of; plant type (tobacco, carrot, rice, barley and others), protein type (industrial proteins & enzymes, therapeutic proteins cell culture functional proteins and others), application (regenerative medicine-therapeutic agents, regenerative medicine-functional material, cell culture application and others), platform (in-vitro culture system, whole plants and others) and end user (biopharmaceutical companies, academic & research institutes, contract research organization (CROS), contract manufacturing organization (CMOS)) across seven prominent regions.

The global plant derived proteins market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

For Information On The Research Approach Used In The Report, Ask Analyst @https://www.futuremarketinsights.com/askus/rep-gb-11038

Plant

Tobacco
Rice
Carrot
Barley
Others

Protein

Industrial Proteins& Enzymes
Therapeutic Proteins
Blood Proteins
Cell Culture Functional Proteins
Others

Platform

In-vitro Cell Culture Systems
Whole Plants
Others

Application

Regenerative Medicine-Therapeutic Agents
Regenerative Medicine-Functional Material
Cell Culture Application
Others

End User

Biopharmaceutical Companies
Academic & Research Institutes
Contract Research Organization (CROs)
Contract Manufacturing Organization (CMOs)

Region

North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East and Africa (MEA)

About FMI:

Contact:

Molybdenum 99 Market Competitive Growth Strategies Based on Type, Applications, End User and Region

The rising incidence of non-communicate diseases is creating scope for novel and advanced imaging technologies. There is immense scope for technologies that offer non-invasive yet precise diagnosis of various types of cancer and cardiovascular ailments. Future Market Insights (FMI) sees the prevailing trends to be highly favorable for the expansion of molybdenum-99 market.

Technetium-99m derived from molybdenum-99 (99Mo) is a key isotope used in radionuclide imaging. It is a part of the technology that non-invasively diagnoses regional metabolic and physiologic processes such as blood flow in the heart to zero down on the affected organ or tissue.

Molybdenum-99 is therefore used as radioisotope in various nuclear medicine diagnostic procedures. With several leading healthcare organizations intending to up their research and development initiatives, the 99Mo is expected to grow considerably in the coming years.

FMI in a recent study has projected the market to rise at a CAGR of 5.2% between 2020 and 2030. The rising willingness among patients and their families to spend on advanced healthcare will bode well for the market. Additionally, government support in the form of favorable reimbursement policies will create lucrative prospects for growth in the coming years.

Request a sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-12424

FMI identifies various growth drivers and restraints impacting the market’s trajectory in its recent study. The report is intended to evaluate the scope for expansion and investment feasibility in the market. Some of the key takeaways from the report are:

The market is estimated to be valued at US$ 3.2 billion by the end of 2020
Supply constraints and looming closure of reactors across various locations are posing threat to growth
Among hospitals and diagnostic centers, the former is expected to account for the maximum revenue generated in the market
North America is expected to remain dominant through the forecast period
Among applications, SPECT segment will hold dominant share in the market

“Companies operating in the market are primarily focusing on research and development to find novel diagnosis methods. Their focus on offering low price therapeutic radiopharmaceuticals is expected to augur well for the market,” said a lead analyst at FMI.

Impact of COVID-19 on MarketThe market for molybdenum-99 is already reeling under inadequate supply. Supply-chain disruptions are not new to the market and the unprecedented pandemic outbreak has only worsened prospects for the market’s growth in 2020.

Ask an Analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-12424

Lockdown orders enforced across the world have caused significant disruptions in production. Partial and complete lockdown followed in the last couple of months have put a serious dent on the global GDP growth.

The negative impact of the same is felt on the molybdenum-99 market as well. North America and South Asia markets will be more hampered. Recovery however is on cards especially once the novel coronavirus passes and economies start focusing on healthcare concerns other than COVID-19.

Who is winning?The market has a consolidated vendor landscape. Tier-1 companies primarily boast dominance. Companies operating in the market primarily focus on research and development initiatives. Besides this, some of them are investing their resources in strategic collaborations and acquisitions to gain competitive advantage.

Other companies such as Advanced Cyclotron Systems, Inc. are focusing on research and development initiatives and establishing facilities in compliance with Good Manufacturing Practices.

Some of the companies profiled in the report are GE Healthcare, IBA, Sumitomo Corporation, Advanced Cyclotron Systems, and Siemens Healthineers.

To Know More About Molybdenum-99 Market:A new market research report published by Future Market Insights (FMI) on the global molybdenum-99 market offers an executive-level blueprint of the market. It offers insights into demand trends and provides analysis of opportunities over the forecast period, 2020-2030. The report examines the market through four different segments – application, end user, and region. The report also provides extensive assessment of pricing by different key market dynamics, life cycle analysis, and technologies that are being deployed in the supply molybdenum-99 and product adoption across several end-use industries.

Ask For Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-12424

Key SegmentsIsotopic Application

SPECT
Gamma Camera

End User

Hospitals
Diagnostic Centers

Regional Outlook

North America (U.S., Canada)
Latin America (Mexico, Brazil, Rest of LATAM)
Europe (Germany, U.K., France, Italy, Spain, Poland, Russia, Rest of Europe)
East Asia (China, Japan, South Korea)
South Asia (India, Thailand, Malaysia, Vietnam, Indonesia)
Oceania (Australia, New Zealand)
Middle East & Africa (GCC Countries, Turkey, Northern Africa, South Africa)

About FMI:

Contact:

Counterfeit Drug Detection Device Market are expected to experience a significant growth of 4.0% CAGR from 2022 to 2029

Counterfeit drugs are substandard and falsified drugs and it is a global problem. Counterfeit Drug Detection Devices are the medical devices that are used to detect the counterfeit chemical composition of the drugs and counterfeit packaging and labeling of the drug. The WHO defines a counterfeit drug as any pharmaceutical product that is deliberately mislabeled with respect to identity and/or source. Counterfeit drugs may include branded and generic products, drugs with the correct ingredients or with the wrong ingredients; without active pharmaceutical ingredient (API), with insufficient active pharmaceutical ingredients (API) or with fake packaging (WHO 2012).

According to World Health Organization (WHO), counterfeit drugs are estimated around 10% of all pharmaceuticals. North America is the largest economy and largest pharmaceutical market in the world and in spite of strict regulatory policies; maximum drugs that market online are counterfeit. As per estimation from WHO in 2012, the loss suffered by pharmaceutical industry for counterfeit drugs were over $75 Bn.

Counterfeit Drug Detection Market: Drivers and Restraints

With increasing incidence of counterfeit drugs in the world the demand for counterfeit drug detection devices are also increasing. According to Pharmaceutical Security Institute, the number of counterfeit drugs incident has increased from 2,193 in 2013 to 3,509 in 2017. Out of these 3,509 incidents, 1,677 are reported in North America. Medications in the anti-infectives, genito-urinary, and central nervous system (CNS) therapeutic categories were mostly counterfeit.

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-7838

Counterfeit drug detection devices have advanced enormously from large laboratory set-up to battery operated handheld gadgets. The ease of use, increased efficiency, on-field result and rapid test result are the major factors fuelling the growth of the concerned market. Several government initiatives to combat the counterfeit drug can also a major reason behind the growth of Counterfeit drug detection devices. For example, U.S. FDA has introduced a counterfeit drug detection device for the identification of counterfeit drug and package, the latest version of this counterfeit drug detection device CD-3 is costs around US$ 1,000.

Policy implementation for unit level track-and-trace is another factor fueling the growth of the market. Increased efforts to combat counterfeit drugs by governments and private companies. German customs have started a project called “Blue Project” which enables government to identify illegal online drug-trading sites and the tracing of financial transactions.

Although lack of awareness about the counterfeit drugs can hamper the growth of counterfeit drug detection device market. People are not aware about the technological advancements in counterfeit drug detection device which impending the adoption of new technology handheld devices of counterfeit drug detection devices and can restrain the growth of counterfeit drug detection device market.

The devices are costly. High cost of counterfeit drug detection device set-up can restrict the growth of counterfeit drug detection device market.

Counterfeit Drug Detection Device Market: Segmentation

To gain a comprehensive and a better understanding of the future market equity, the Counterfeit Drug Detection Device market report is segmented based on technology, application, end user and region.

Based on the technology type Counterfeit Drug Detection Device is segmented into:

Infrared and Near Infrared Spectroscopy
Ultraviolet/Vis
Microfluidic
Raman Spectroscopy
Rapid Chemical Testing
X-ray diffraction (XRD) and X-ray fluorescence (XRF) Spectroscopy
RFID Technology
Scanning and Imaging Systems
Other Packaging and Labelling Counterfeit Drug Detection Device

For Information On The Research Approach Used In The Report, Ask Analyst @ https://www.futuremarketinsights.com/askus/rep-gb-7838

Based on application Counterfeit Drug Detection Device Market can be segmented into:

Counterfeit Drug Detection Device for Chemical Composition
Counterfeit Drug Detection Device for Packaging & Labelling Detection

Based on end user, Counterfeit Drug Detection Device Market can be segmented into:

Pharmaceutical companies
Drug testing laboratories
Research organizations

On the basis of geography, Counterfeit Drug Detection Device can be segmented as:

North- America
Eastern Europe
Western Europe
Asia-Pacific excluding China & Japan
China
Japan
Middle East and Africa
Latin America

Counterfeit Drug Detection Device Market: Overview

Global Counterfeit Drug Detection Device market has witnessed a growth due to increasing incident of counterfeit drugs. Moreover ease of use, increased efficiency, on-field result and rapid test result are the major factors fuelling the growth of Counterfeit Drug Detection Device Market.

Among the various types of Counterfeit Drug Detection device market for Raman spectroscopy based devices are dominating for counterfeit drug detection. The usage of Raman and NIR spectroscopy is much higher as the techniques complement each other

Among the various types of Counterfeit Drug Detection application, preclinical application is dominating due to its vast use in ex vivo experiments and drug efficiency monitoring on small animal.

Counterfeit Drug Detection Devices can be used for the detection of counterfeit drug composition and counterfeit Packaging & Labeling Detection.

Counterfeit Drug Detection Device Market: Region-wise Outlook

Geography wise, Counterfeit Drug Detection Device Market is divided into eight regions viz. North-America, Asia- Pacific excluding China & Japan, China, Japan, Western Europe, Eastern Europe, Latin America and Middle-East & Africa. North America’s Counterfeit Drug Detection Device Market is expanding because of healthcare spending and healthcare infrastructure and it will remain dominant over the period of forecast. Latin America Counterfeit Drug Detection Device Market is anticipated to grow at a moderate rate due to poor awareness and low healthcare expenditure.

Counterfeit Drug Detection Device Market: Key Market Participants

Some of the market participants in the Global Counterfeit Drug Detection Device market identified across the value chain include: DNA Technologies, ASD Inc., Consumer Physics Inc., DuPont, Global Pharma Health Fund E.V., GAO RFID, Inc., AlpVision, Global Pharma Health Fund E.V., Olympus Corporation, Snowy Range Instruments, Thermo Fisher Scientific, Inc.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

About FMI:

Contact:

PD-L1 Biomarker Testing Market is projected to reach a valuation of US$ 597.9 Million in 2022

As the prevalence of lung cancer, melanoma, and renal cell carcinoma continues to soar worldwide, the adoption of PD-L1 biomarker testing is expected to grow at a healthy pace in the years to come, says Future Market Insights (FMI) in its new market study. Moreover, the report forecasts that the global PD-L1 biomarker testing market will grow in value at a stellar CAGR of 9.4% between 2022 and 2032.

The report opines that the outbreak of COVID-19 is likely to create short-term fluctuations on the supply side due to pandemic-related issues such as workforce shortages and disruptions of delivery networks. Similarly, a steep decline in the number of tests has been observed during the pandemic, and this is expected to further decelerate the demand for PD-L1 biomarker testing.

The report primarily attributes the growth of the market to the increasing incidence of cancers, especially lung and skin, coupled with the development of advanced diagnostic kits and assays.

Request a sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-5897

Likewise, rising awareness regarding the availability of testing methodology such as immunohistochemistry-based assays and Enzyme-linked Immunoassay (ELISA) based detection will continue to impel the adoption of PD-L1 biomarkers in the forthcoming years.

Key Takeaways

The global PD-L1 biomarkers testing market is expected to surge past valuation of US$ 2.05 Bn by the end of the forecast period.
PD-L1 SP142 assay kits will remain the most popular products among end-users, capturing nearly half of the market value, owing to high efficiency in detecting cancer tumors.
Non-small cell lung cancer and melanoma are cumulatively expected to hold more than 50% of the total market value on the back of the soaring prevalence of these diseases.
By end-use, PD-lL1 biomarker testing finds the majority of applications in hospitals, which is expected to account for over 60% of market value.
North America will spearhead the regional landscape through the forecast period, accounting for more than 50% of the global market value.
Europe is poised to remain the second most lucrative region, holding nearly 1/3rd of market value.

“Market players are directing their efforts towards improving the accessibility of these products and are marking them cost-effective to ensure wide-scale adoption,” remarks FMI analyst.

COVID-19 Impact on PD-L1 Biomarker Testing Market

The COVID-19 pandemic has created disruptions across the healthcare technology landscape and has resulted in a shifting preference among manufacturers towards essential technologies and treatments. Furthermore, although PD-L1 biomarker testing is used to test severe diseases such as cancer, a reduced number of screenings is adversely impacting the demand for testing.

Ask an Analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-5897

For instance, according to trends observed by Cancer Research Network, screening rates of melanoma plummeted by approximately 50% in the UK in the past few months. Likewise, in the US, the number of tests conducted to detect non-small cell lung cancer fell by 30% in March as compared to February. As patients reschedule or skip regular screenings, this is creating a downtrend in demand for PL-D1 biomarker testing.

However, considering the severity of these diseases, the need for testing will swiftly arise in the future, ensuring that the market’s growth trajectory remains intact.

Who is Winning?

Key players operating in the market are focusing on enhancing existing product designs and developing novel products with increased accuracy. Moreover, traditional growth strategies such as acquisitions and mergers have been identified as strategies adopted by players to strengthen their foothold in the competitive landscape.

In January 2019, Abcam Plc acquired Calico Biolabs with an objective to expand its custom monoclonal production service capabilities.
In December 2018, NeoGenomics, Inc. acquired Genoptix, Inc. to improve its oncology diagnostic services.

FMI’s report includes profiles of some of the most prominent names in the market including F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., NeoGenomics Laboratories, Inc, HalioDx and Abcam plc. among others.

To Know More About PD-L1 Biomarkers Market

A new market research report published by Future Market Insights (FMI) on the global PD-L1 biomarkers market offers an executive-level blueprint of the market. It offers insights into demand trends and provides analysis of opportunities over the forecast period, 2022-2032. The report examines the market through four different segments – product, indication, end-use, and region. The report also provides extensive assessment of pricing by different key market dynamics, life cycle analysis, and technologies that are being deployed in the supply and product adoption across several end-use industries.

Ask For Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-5897

About FMI:

Contact:

Physical Security Equipment Market Recent Trends, Demand, Dynamic Innovation in Technology & Insights | Future Market Insights, Inc.

Recent research by Future Market Insights (FMI) has estimated the global physical security equipment market to reach nearly US$ 64,000 Mn in revenues by 2022-end. Over the forecast period (2017-2022), the global market for physical security equipment is projected to exhibit a staggering expansion at over 10% CAGR.

Emergence of Thermal Cameras – A Major Trend Observed in the Market

A major trend being discerned in the market is the emergence of thermal cameras. As these cameras are water & heat resistant, and use infrared radiation for taking images, they have evolved an indispensable part of physical security equipment in observing unique/large-scale outdoor environments.

Several institutions and critical infrastructures are being offered grants by governments for purchasing efficient surveillance equipment. The requirement for sophisticated security systems that help in ensuring safety of data has led the organisations to adopt data analytics, along with cloud-based data storages.

Request a Sample Copy of the Report @
https://www.futuremarketinsights.com/reports/sample/rep-gb-4975

The nature of the global physical security equipment market is highly fragmented, with presence of various large- as well as small-scale vendors competing for gaining larger market share.

These vendors are concentrating on providing innovative and highly-efficient security solutions coupled with customized security services for sustaining their presence in the market. In addition, they are also providing integrated security systems, which ensure optimum security. Global leaders in the market are adopting key strategies such as M&A, and are acquiring niche players, in a bid to enhance their product portfolio.

Organisations Adopting Physical Security Equipment for Safeguarding their Personnel & Property

It has become pivotal for different institutions around the world to adopt physical security equipment on the back of surging threats related to physical damage and attacks. Various organisations from end-use sectors including transportation, commercial, utilities & energy retail, residential, government, manufacturing, education, healthcare and BFSI are adopting physical security equipment for safeguarding their property as well as personnel.

The elevation in threats pertaining to terrorism across the globe has led the organisations and governments to spend more on latest and highly advanced security solutions, for ensuring safety of physical sites and people working there. Increasing incidences of espionage and thefts, particularly in banking sector and commercial buildings, are further driving adoption of physical security equipment worldwide.

Ask for Customization @
https://www.futuremarketinsights.com/customization-available/rep-gb-4975

Key Insights from FMI’s Report on Global Physical Security Equipment Market

Asia-Pacific excluding Japan (APEJ) is anticipated to remain the fastest-growing market for physical security equipment. By the end of forecast period, APEJ will become the second most lucrative region for growth of the market. Government agencies in APEJ are increasingly deploying physical security equipment in public and transportation security, especially in China and India. In addition, soaring IT sector, coupled with rapid industrialisation in APEJ countries will further drive the market growth.
Sales of physical security equipment in government vertical segment are projected to register the highest CAGR through 2022. In addition, although healthcare vertical currently accounts for relatively lower revenue share of the market, it will exhibit an impressive expansion over the forecast period. BFSI is expected to remain the second largest vertical in the global physical security equipment market.
Consumer video surveillance will continue to be the most attractive physical security equipment, followed by thermal cameras and wireless infrastructure. Revenues from consumer video surveillance, thermal cameras and wireless infrastructure will collectively account for nearly two-third share of the market throughout the forecast period.

Competitive Landscape

FMI’s report has listed key players that are actively operating in the global physical security equipment market, which include Montaplast GmbH, Valeo SA, The Chamberlain Group, Inc., Siemens AG, Bosch Security Systems, Inc., United Technologies Corporation, Zhejiang Dahua Technology Co., Ltd., Hangzhou Hikvision Digital Technology Co., Ltd., Axis AB, Hanwha Techwin Co., Ltd., Johnson Controls International Plc, and Schneider Electric SE.

Request a Complete TOC of this Report with figures @
https://www.futuremarketinsights.com/toc/rep-gb-4975

Market Taxonomy

Region:

North America
Latin America
Europe
Japan
APEJ
MEA

Security Equipment:

Video Surveillance
Access Control
Intruder Alarms
Entrance Control
Consumer Video Surveillance
thermal Cameras
Wireless Infrastructure

Vertical:

BFSI
Education
Healthcare
Government
Manufacturing
Retail
Residential
Transportation
Utilities & Energy
Commercial

https://community-specialists.tribe.so/post/procurement-software-market-current-scenario-trends-comprehensive-analysis—62ebd5fb67ec7b1331039a7f

https://speaknow.tribe.so/post/procurement-software-market—latest-research-industry-analysis-driver-tren–62ebd5fc29387d22d1491cc3

https://howtolive.tribe.so/post/procurement-software-market-worldwide-industry-analysis-and-new-market-oppo–62ebd5fd81130437d5721413

About Us

Contact:

Future Market Insights Inc.  
Christiana Corporate,
200 Continental Drive,
Suite 401, Newark,
Delaware – 19713, USA  
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Browse latest Market Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs

Loop-mediated Isothermal Amplification (LAMP) Market is expected to reach US$ 120.4 Million by 2028

Global demand for loop-mediated isothermal amplification technology reached around US$ 85 million in 2018, as indicated by a new research study of Future Market Insights (FMI). Estimated to observe stable growth in revenue over the coming years, loop-mediated isothermal amplification market will witness dominance of DNA polymerase, among the various product types.

Dominance of DNA Polymerase Adoption to Prevail, LAMP Instruments to Emerge Lucrative

DNA polymerase will continue to find highest applicability in both research and diagnostics. According to FMI’s report, DNA polymerase will be the key revenue generating product in loop-mediated isothermal amplification market over the period of projection. However, the report also highlights that instruments such as turbidimeters and fluorescence measuring systems will prominent traction in loop-mediated isothermal amplification market through 2028.

Amongst various loop-mediated isothermal amplification technologies, micro-fluidic technology majorly, have been successfully used in the diagnosis of several diseases including malaria and tuberculosis. Loop-mediated isothermal amplification using DNA polymerase has seen a rapid rise in the past several years due to the high adoption of loop-mediated isothermal amplification in testing.

Request a sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-5532

The application of these Loop-mediated isothermal amplification in assessing and directing diagnosis in certain types of disease, such as acute malaria, has provided a new dimension to the gradually growing field of minimal residual disease management.

High Penetration of Cutting-edge Technology Molecular Diagnostics of Fatal Diseases to Push LAMP Market Growth

The simplicity sensibility and specificity of loop-mediated isothermal amplification puts it in a very good position for future development in life threatening disease diagnosis. It is anticipated that the loop-mediated isothermal amplification market will grow significantly during the forecast period, owing mainly due to demand for advanced molecular diagnostics to accurately diagnose life-threatening diseases.

In recent years, the detection and identification of nucleic acids using point-of-care total nucleic acid analysis systems and procedures are in rise including loop-mediated isothermal amplification in various clinical and industrial settings. Besides loop-mediated isothermal amplification has also challenged PCR based amplification as it could achieve enhanced nucleic acid amplification by increasing surface area to volume ratio with reduced testing cost.

Macroeconomic indicators such as government funding for advancement and increased research on disease epigenetics; establishment of network of distribution and marketing agreements to ensure availability of products to different loop-mediated isothermal amplification end users globally; liberalization of import and export trade on point of care diagnostic devices and chemical reagents are also anticipated to propel the growth of the loop-mediated isothermal amplification market.

Ask an Analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-5532

Key Challenges Facing Development of Loop-mediated Isothermal Amplification Market

On the grey side, loop-mediated isothermal amplification has several intrinsic disadvantages such as its amplification method is devoid of an internal PCR inhibition control (IC). It is essential to perform all the reactions in duplicate, one being or the target and the other one for the IC in loop-mediated isothermal amplification assay.

Moreover, most standard DNA polymerases are unable to exhibit activity in samples derived from crude lysate due to the presence of polymerase inhibitors. This adds complexity to the loop-mediated isothermal amplification processing due to additional steps involved in purifying DNA to be used for amplification, which could also result in loss of starting material.

Loop-Mediated Isothermal Amplification Market: Additional Questions Answered

What is the revenue potential of the Loop-Mediated Isothermal Amplification Markets across North America and Europe?
Who are the key competitors and what are their portfolios in the Loop-Mediated Isothermal Amplification Market?
What are the major challenges influencing the growth of the Loop-Mediated Isothermal Amplification Market?
How is intervention from regulatory authorities shaping the growth of the Loop-Mediated Isothermal Amplification Market?

Regions with High Disease Prevalence to Reflect High Growth Potential for LAMP Market

Due to increase in prevalence of malaria and other pandemic diseases, regions such as East and South Asia are anticipated to be the fastest growing regional loop-mediated isothermal amplification markets and are poised to offer tremendous opportunities to key players.

The increase in disease prevalence will increase the demand for the use of loop-mediated isothermal amplification for point-of-care diagnosis. Besides, distribution & collaboration agreements by leading players of loop-mediated isothermal amplification products with the established local distributors in the regions will fuel the market growth of both the regions.

The loop-mediated isothermal amplification market report tracks some of the key companies operating in the global loop-mediated isothermal amplification market such as :

Eiken Chemcial Co.Ltd
New England Biolabs
Jena Bioscience GmbH
NIPPON GENE CO.
LTD
HUMAN
Optigene
HiberGene Diagnostics
Meridian Bioscience Inc.
Mast Group Ltd.

Ask For Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-5532

Key Segment

Based on product type

instruments
- incubation systemsTurbidimeters
- Agarose gel electrophoresis
- fluorescence measuring systems
kits & reagents
- DNA polymerase
- Primer Mix
- DNA Polymerase &Primer mix
- dyes
- other reagents

Based on Technology

microfluidic technology
advanced infrared optical technology
modern microsystem technology

Based on Application

diagnostic
research purpose

Based on End User

hospital & laboratories
research & academic institutes
others

About FMI:

Contact:

APOL1 Mediated Kidney Disease Market is predicted to witness a steady CAGR of over 4% during the forecast period by 2030

The current treatment options are limited and they are effective only against the symptoms of APOL1 medicated kidney diseases such as inflammations, high fluid volume, and hypertension. Because of this, there is an urgency of novel and targeted therapeutics which can target to reduce APOL1 protein level in the body. Excess APOL1 causes nephropathic conditions and ultimately kidney failure in people having APOL1 mediated disorder.

According to a latest report published by Future Market Insights (FMI), the global APOL1 mediated kidney disease market was valued at US$ 3.0 Bn in 2020 and is anticipated to witness a steady CAGR of over 4% during the forecast period (2020-2030).

Currently, the leading clinical stage biopharmaceutical developers are focusing on development of next generation targeted therapeutics against APOL1 medicated kidney diseases, specifically chronic kidney diseases. The promising yet unmet opportunities for APOL1 medicated kidney diseases are attracting established and new biopharmaceuticals to dive in the targeted therapeutic based approach. This trend is expected to offer competitive-edge and exclusive monopoly in the global market in the future.

Request a sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-12115

For instance, in 2018, AstraZeneca closed a $330 million licensing agreement for two pipeline antisense therapies of Ionis Pharmaceuticals, Inc. a U. S. based clinical stage Innovator Company engaged in the advanced research of rare diseases. One of licensed therapeutic is investigational novel antisense drug (AZD2373) to treat original cause of the APOL1 mediated chronic kidney diseases. AZD2373 is currently under clinical phase I and is looking a promising candidate for the future APOL1 mediated kidney diseases landscape.

Key Takeaways from APOL1 Mediated kidney Diseases Market Study

Chronic kidney diseases account for more than 95% of all the APOL1 mediated diseases. Increasing prevalence of hypertension associated kidney diseases will increase treatment needs over the forecast period
North America accounts for over 3/4th of the global market. High prevalence of the disease among people with African American ancestry makes North America the leader in this market
Pipeline drugs under development are targeted to be launched in the U.S., catapulting it as a highly lucrative pocket
Key players are focusing on extensive research and development for targeted therapy towards APOL1
The COVID-19 outbreak did not have any impact on the APOl1 mediated treatment market. All patients with indications like end stage kidney disorders were attended amidst COVID-19 due to the severity of kidney disease

Who is winning?

Collaboration is the key strategy amongst market players. Companies research on APOL1 therapies are strengthening their chances of successful clinical trials by collaborating with prominent pharma players. Increasing investments in drug discovery is expected to favor the growth the global market over the forecast period

For instance, Ionis Pharma has collaborated with AstraZeneca for developing its molecule which is currently under clinical trial phase 1.

Ask an Analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-12115

Want more insights?

Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2015-2030. The global APOL1 mediated kidney disease market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on APOL1 mediated kidney disease (Symptomatic Treatment) market on basis of indication (Chronic Kidney Disease and End Stage Kidney Disease) across North America, Europe and Middle East and Africa and APOL1 mediated kidney disease (Pipeline Therapeutics) market on basis of indication (Chronic Kidney Disease and End Stage Kidney Disease) across North America (U.S.)

APOL1 mediated kidney diseases (Symptomatic Treatment) Market

ByIndication

Chronic Kidney Disease
Focal segmental glomerulosclerosis (FSGS)
Human immunodeficiency virus (HIV)-associated Nephropathy
Hypertension-associated Kidney Disease
End-Stage Kidney Disease

Region

North America (U.S.)
Europe
MEA

Ask For Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-12115

About FMI:

Contact:

Antibodies Market Current and Future Demand, Analysis, Growth and Forecast By 2031

The antibodies market is expected to reach market valuation of US$ 186.865 Billion in 2021. The growth can be attributed to high versatility of antibodies in treating wide array of ailments and high demand for antibody cocktails to treat COVID-19.

Antibodies market is very competitive with F. Hoffmann-La Roche Ltd., AbbVie Inc., Johnson & Johnson Services Inc., Amgen Inc., and Bristol-Myers Squibb Company holding around 75% of global market shares as of 2021.

As per the National Institute of Health, autoimmune diseases are more prevalent in women as compared to men and are also the leading cause of death in women under the age 65. Rising incidence of autoimmune diseases like diabetes and scleroderma in women will boost the demand for antibodies in forthcoming years.

The COVID-19 pandemic accelerated the demand for antibody therapeutics as it has been found effective in treating COVID-19 patients that are non hospitalized but are highly susceptible to contracting various other ailments. In some cases COVID-19 triggered the autoimmune diseases in the patient further increasing the demand.

Surge in number of Parkinson’s disease and Alzheimer patients and rising necessity to create affordable antibody therapeutics for population in low income countries will accelerate the market growth.

Increased number of drugs at various phases of clinical trials and rising drug approval rates from concerning authorities will drive the market for antibodies.

Request a sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1330

However, high cost of biologics is a growing concern as it increases healthcare cost. Rising economic load of cancer and other ailments is accelerating the healthcare spending.

With incorporation of modern production techniques for manufacturing therapeutic antibodies will promote the market penetration in cost sensitive regions like Asian market.

Key Takeaways from FMI’s Antibodies Market Study

The U.S. is expected to lead the antibodies market during the assessment period due to presence of leading antibody drugs manufacturers, increased consumer spending on healthcare and rising incidences of autoimmune and other chronic ailments in the country.
Rising prevalence of cancer and establishment of modern pharmaceutical and medical research centers in Saudi Arabia will drive the antibodies market growth in the country.
China is forecast to exhibit tremendous growth owing to increased government spending on healthcare, heightened production of antibodies therapeutics and growing geriatric population in the country.
Rapid technological advancements in healthcare sector, increasing government funding to make the treatment affordable, and increasing consumer spending on healthcare will create opportunities for market growth in India.
Rising prevalence of non-Hodgkin lymphoma and other type of cancer along with increasing demand for non invasive treatment options will fuel the demand for cancer antibodies
Monoclonal antibodies are forecast to exhibit high demand throughout the forecast period owing to rising drug approval rates and increasing cases of rheumatoid arthritis, psoriasis, and asthma in geriatric population across the globe.
“Rising effectiveness of antibody cocktails in treating COVID-19 especially in at risk patients will boost the antibodies market growth throughout the forecast period,” says the FMI analyst.

Ask an Analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-1330

Competitive Landscape

Antibodies market is consolidated as top antibodies producers hold 75% of global market share. New product development is the key area of focus among market players in order to strengthen their market position.

They are also involved in performing extensive research and development for product portfolio expansion. They are also working towards developing cheaper antibody therapeutics to penetrate the new markets and capture maximum market share especially in emerging economies.

Some market players are emphasizing on strategic merger and acquisition and partnership with other market players for rapid roll out of drugs and portfolio expansion. They are also emphasizing towards faster product approvals across various government agencies.

Bristol-Myers Squibb Company entered into an exclusive strategic collaboration with Eisai Co. Ltd. for the co-development and co-commercialization of an antibody-drug complex called “MORAb-202” on 17^th June 2021.

In January 2021, Sanofi announced to acquire Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies at around US$ 1.1 Bn. The aim of the acquisition is to focus on developing immune-mediated diseases and immuno-oncology therapeutics.

Prominent players operating in the antibodies market are:-

Novartis AG
F. Hoffmann-La Roche AG
Johnson & Johnson
Takeda Pharmaceutical Company Limited
Amgen Inc.
Biogen Inc.
Bristol-Myers Squibb Company
AbbVie Inc.
Sanofi SA
Eli Lilly and Co.

Ask For Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-1330

About FMI:

Contact:

DNA Polymerase Market to exhibit a CAGR of approximately 6.5% during the forecast period by 2031

A growing number of drug patent expirations and the interest in generic biologics has gained significantly from developments in the DNA polymerase market. Rising demand for improvements in healthcare diagnostics are expected to remain key influencer in market growth. According to Future Market Insights, a new study has forecast the DNA polymerase market to exhibit a CAGR of approximately 6.5% during the forecast period from 2021 to 2031.

Major manufacturers in the DNA polymerase market are increasingly focused on investing in research and development efforts to widen the scope of applications in the sector. In addition, strategic acquisitions and collaborations to share expertise, leveraging biopharmaceuticals and contract manufacturing companies will find ground in the industry.

In terms of end users, molecular diagnostics companies are likely to remain primary contributors to the market accounting for more than 30% of the global market share. Furthermore, academic and research institutes will display a relatively faster rate of growth, driven by investments into R&D for accuracy in diagnostics, genome research, DNA cloning, and potential applications in cancer research.

Request a sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-801

Increasing R&D activities is a key factor positively influencing the development and use of high-fidelity DNA polymerase. Increasing incidences of cancer, concerns over uncontrolled genetic mutations, increasing awareness on neurological disorders, and potential for treating chronic diseases create lucrative opportunities in the DNA polymerase market. Also, the growing importance being given to personalized medicine will provide impetus to market players through the coming decade.

On the other hand, DNA polymerase market players are expected to face a number of challenges during the forecast period. For instance, shortage of adequately skilled professionals is a restraining factor affecting the market. Lack of information and awareness associated to DNA polymerase also affects sales prospects. Also, a shortage of funding by governments in the sector are restraining market growth. These factors are especially true in developing countries with restricted access to capital and infrastructure.

Key Takeaways from DNA Polymerase Market Study

The global DNA polymerase market is projected to grow at approximately 6.5% CAGR through the projection period.
Molecular diagnostic applications will account for major market, with impetus from the covid-19 pandemic.
The U.S. will hold the lead in North America accounting for more than 50% of the global valuation.
China will reflect high growth potential accounting for a CAGR of over 7.5%, owing to rising healthcare spending.
UK will reflect high demand in Europe supported by the rise of contract research and manufacturing organizations in biopharmaceuticals.

“The introduction of numerous government initiatives and rising levels of government funding efforts for R&D activities, are key factors that are expected to bolster the growth of high-fidelity DNA polymerase offerings. Furthermore, the increasing occurrence of genetic disease, is also one of the major factors supporting growth in the market through the assessment period,” said an FMI analyst.

Ask an Analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-801

Who is Winning?

The global DNA polymerase market is set to widen its scope of expansion through the assessment period, driven by a higher rate of adoption in molecular diagnostics, bioprocessing, cancer research and development of generic biologics in the biopharmaceutical sector. A shortage of adequately skilled professionals and lack of awareness has restrained revenue in the industry.

Some of the more prominent players in the DNA polymerase market include but are not limited to Thermo Fisher Scientific Inc., Hoffmann-La Roche AG, Merck KGaA, Qiagen N.V., Agilent Technologies Inc., Takara Bio Inc., Genescript, Illumina Inc., New England Biolabs, Inc., Bioline, and Promega Corporation.

Want More Insights?

Future Market Insights provides an exhaustive report in terms of forecast on global, regional, and country levels, with actionable insights on the latest industry trends in key segments from 2016 to 2031. The DNA polymerase market is segmented in detail to encompass all aspects, providing readers with a complete market intelligence report approach. The study provides details on the basis of product type (prokaryotic and eukaryotic), and end use (molecular diagnostics companies, diagnostic laboratories, academic and research institutes, biopharmaceutical companies, and hospitals), across seven major regions.

Ask For Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-801

About FMI:

Contact: